Engineered regulatory T cells coexpressing MHC class II

Peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis

Zhaohui Qian, Kary A. Latham, Karen B. Whittington, David C. Miller, David Brand, Edward F. Rosloniec

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Regulatory T cells (Tregs) are critical homeostatic components in preventing the development of autoimmunity, and are a major focus for their therapeutic potential for autoimmune diseases. To enhance the efficacy of Tregs in adoptive therapy, we developed a strategy for generating engineered Tregs that have the capacity to target autoimmune T cells in an Ag-specific manner. Using a retroviral expression system encoding Foxp3 and HLA-DR1 covalently linked to the immunodominant peptide of the autoantigen type II collagen (DR1-CII), naive T cells were engineered to become Tregs that express DR1-CII complexes on their surface. When these cells were tested for their ability to prevent the development of collagen induced arthritis, both the engineered DR1-CII-Foxp3 and Foxp3 only Tregs significantly reduced the severity and incidence of disease. However, the mechanism by which these two populations of Tregs inhibited disease differed significantly. Disease inhibition by the DR1-CII-Foxp3 Tregs was accompanied by significantly lower numbers of autoimmune CII-specific T cells in vivo and lower levels of autoantibodies in comparison with engineered Tregs expressing Foxp3 alone. In addition, the numbers of IFN-γ- and IL-17-expressing T cells in mice treated with DR1-CII-Foxp3 Tregs were also significantly reduced in comparison with mice treated with Foxp3 engineered Tregs or vector control cells. These data indicate that the coexpression of class II autoantigen-peptide complexes on Tregs provides these cells with a distinct capacity to regulate autoimmune T cell responses that differs from that used by conventional Tregs.

Original languageEnglish (US)
Pages (from-to)5382-5391
Number of pages10
JournalJournal of Immunology
Volume190
Issue number11
DOIs
StatePublished - Jun 1 2013

Fingerprint

Regulatory T-Lymphocytes
Arthritis
T-Lymphocytes
Peptides
Autoantigens
HLA-DR1 Antigen
Experimental Arthritis
Collagen Type II
Interleukin-17
Autoimmunity
Autoantibodies
Autoimmune Diseases
Incidence
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Engineered regulatory T cells coexpressing MHC class II : Peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis. / Qian, Zhaohui; Latham, Kary A.; Whittington, Karen B.; Miller, David C.; Brand, David; Rosloniec, Edward F.

In: Journal of Immunology, Vol. 190, No. 11, 01.06.2013, p. 5382-5391.

Research output: Contribution to journalArticle

Qian, Zhaohui ; Latham, Kary A. ; Whittington, Karen B. ; Miller, David C. ; Brand, David ; Rosloniec, Edward F. / Engineered regulatory T cells coexpressing MHC class II : Peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis. In: Journal of Immunology. 2013 ; Vol. 190, No. 11. pp. 5382-5391.
@article{73fc6ef2db014d57a18801e3b72e38ae,
title = "Engineered regulatory T cells coexpressing MHC class II: Peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis",
abstract = "Regulatory T cells (Tregs) are critical homeostatic components in preventing the development of autoimmunity, and are a major focus for their therapeutic potential for autoimmune diseases. To enhance the efficacy of Tregs in adoptive therapy, we developed a strategy for generating engineered Tregs that have the capacity to target autoimmune T cells in an Ag-specific manner. Using a retroviral expression system encoding Foxp3 and HLA-DR1 covalently linked to the immunodominant peptide of the autoantigen type II collagen (DR1-CII), naive T cells were engineered to become Tregs that express DR1-CII complexes on their surface. When these cells were tested for their ability to prevent the development of collagen induced arthritis, both the engineered DR1-CII-Foxp3 and Foxp3 only Tregs significantly reduced the severity and incidence of disease. However, the mechanism by which these two populations of Tregs inhibited disease differed significantly. Disease inhibition by the DR1-CII-Foxp3 Tregs was accompanied by significantly lower numbers of autoimmune CII-specific T cells in vivo and lower levels of autoantibodies in comparison with engineered Tregs expressing Foxp3 alone. In addition, the numbers of IFN-γ- and IL-17-expressing T cells in mice treated with DR1-CII-Foxp3 Tregs were also significantly reduced in comparison with mice treated with Foxp3 engineered Tregs or vector control cells. These data indicate that the coexpression of class II autoantigen-peptide complexes on Tregs provides these cells with a distinct capacity to regulate autoimmune T cell responses that differs from that used by conventional Tregs.",
author = "Zhaohui Qian and Latham, {Kary A.} and Whittington, {Karen B.} and Miller, {David C.} and David Brand and Rosloniec, {Edward F.}",
year = "2013",
month = "6",
day = "1",
doi = "10.4049/jimmunol.1300024",
language = "English (US)",
volume = "190",
pages = "5382--5391",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - Engineered regulatory T cells coexpressing MHC class II

T2 - Peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis

AU - Qian, Zhaohui

AU - Latham, Kary A.

AU - Whittington, Karen B.

AU - Miller, David C.

AU - Brand, David

AU - Rosloniec, Edward F.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Regulatory T cells (Tregs) are critical homeostatic components in preventing the development of autoimmunity, and are a major focus for their therapeutic potential for autoimmune diseases. To enhance the efficacy of Tregs in adoptive therapy, we developed a strategy for generating engineered Tregs that have the capacity to target autoimmune T cells in an Ag-specific manner. Using a retroviral expression system encoding Foxp3 and HLA-DR1 covalently linked to the immunodominant peptide of the autoantigen type II collagen (DR1-CII), naive T cells were engineered to become Tregs that express DR1-CII complexes on their surface. When these cells were tested for their ability to prevent the development of collagen induced arthritis, both the engineered DR1-CII-Foxp3 and Foxp3 only Tregs significantly reduced the severity and incidence of disease. However, the mechanism by which these two populations of Tregs inhibited disease differed significantly. Disease inhibition by the DR1-CII-Foxp3 Tregs was accompanied by significantly lower numbers of autoimmune CII-specific T cells in vivo and lower levels of autoantibodies in comparison with engineered Tregs expressing Foxp3 alone. In addition, the numbers of IFN-γ- and IL-17-expressing T cells in mice treated with DR1-CII-Foxp3 Tregs were also significantly reduced in comparison with mice treated with Foxp3 engineered Tregs or vector control cells. These data indicate that the coexpression of class II autoantigen-peptide complexes on Tregs provides these cells with a distinct capacity to regulate autoimmune T cell responses that differs from that used by conventional Tregs.

AB - Regulatory T cells (Tregs) are critical homeostatic components in preventing the development of autoimmunity, and are a major focus for their therapeutic potential for autoimmune diseases. To enhance the efficacy of Tregs in adoptive therapy, we developed a strategy for generating engineered Tregs that have the capacity to target autoimmune T cells in an Ag-specific manner. Using a retroviral expression system encoding Foxp3 and HLA-DR1 covalently linked to the immunodominant peptide of the autoantigen type II collagen (DR1-CII), naive T cells were engineered to become Tregs that express DR1-CII complexes on their surface. When these cells were tested for their ability to prevent the development of collagen induced arthritis, both the engineered DR1-CII-Foxp3 and Foxp3 only Tregs significantly reduced the severity and incidence of disease. However, the mechanism by which these two populations of Tregs inhibited disease differed significantly. Disease inhibition by the DR1-CII-Foxp3 Tregs was accompanied by significantly lower numbers of autoimmune CII-specific T cells in vivo and lower levels of autoantibodies in comparison with engineered Tregs expressing Foxp3 alone. In addition, the numbers of IFN-γ- and IL-17-expressing T cells in mice treated with DR1-CII-Foxp3 Tregs were also significantly reduced in comparison with mice treated with Foxp3 engineered Tregs or vector control cells. These data indicate that the coexpression of class II autoantigen-peptide complexes on Tregs provides these cells with a distinct capacity to regulate autoimmune T cell responses that differs from that used by conventional Tregs.

UR - http://www.scopus.com/inward/record.url?scp=84878081603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878081603&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1300024

DO - 10.4049/jimmunol.1300024

M3 - Article

VL - 190

SP - 5382

EP - 5391

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -